Connbey: Revenue of RMB3,577 million Net profit up 42.62%

On the evening of July 11, 2018, Conebey released its 2018 Half-Year Results Express. According to the express report, Connbey achieved operating income of 3.577 billion yuan in the first half of the year, an increase of 52.83 percent over the same period last year, of which the pharmaceutical industry's operating income was 3.490 billion yuan, accounting for 97.57 percent of the reported operating income, an increase of 56.59 percent over the same period last year, and realized an operating profit of 647 million yuan. 39.60 percent year-on-year; realized total profit of 648 million yuan, up 39.65 percent year-on-year; and realized net profit attributable to shareholders of listed companies and net profit attributable to shareholders of listed companies of 548 million yuan and 487 million yuan, up 42.62 percent and 25.63 percent year-on-year, respectively.
the first half of 2018, Connbe's large-brand large-variety project continued to maintain a good momentum of development. According to statistics, the series of brand products included in its large-brand large-variety engineering projects achieved a cumulative sales revenue of 2.629 billion yuan, an increase of 69.67 percent over the same period last year. Among them: "Connbey" enteritis Ning series, "Front Kang" brand Pulian and Tansorosin series of products, "Golden Flute" brand compound fishy grass compound and "Treasure Ming" brand eye drops and eye health products in the first half of 2018 sales revenue reached 377 million Yuan, 241 million yuan, 202 million yuan, 194 million yuan, an increase of 30.31 percent, 51.22 percent, 243.07 percent and 46.71 percent, respectively, over the same period last year; Bay "brand musk heart drop pill products, "Golden Kang Express" brand acetyl cysteine foam tablets and other brand products sales revenue increased by more than 40% YoY; Two years of decline and showed a steady recovery, in the first half of 2018 the number of sales of this product reached 47.42 million units, up 19.30% YoY, sales revenue of 894 million yuan, up 200.48% YoY (of which the gradual implementation of the "two-vote system" The increase in sales revenue resulting from the price policy was $547 million, excluding a 26.84% increase in the compared calibre of this factor.
's continued rapid growth since 2017 has been remarkable. Previously, Xinkang has published a ranking| 2016-2017 domestic pharmaceutical industry listed enterprises industrial strength ranking, in the pharmaceutical industry sales annual revenue of more than 5 billion listed companies, Kang Enbei's industrial revenue growth rate ranked in the top three, at the same time, is also the growth of the Chinese medicine industry leader.
the growth logic behind Connbey as a Chinese medicine industry?
first of all, thanks to innovations in its institutions and mechanisms. It is understood that in April last year, Kang Enbei launched the new Long March 1 project - large-brand large varieties of projects, reconfiguration and optimization of related resources, to stimulate the management team efforts, the establishment of cross-subsidiary, cross-departmental management system, to carry out the relevant large-scale brand varieties of the whole, the whole process, full cycle, the whole industry chain management, and achieved good results. Secondly, it perfects the multi-level co-creation sharing system, including the core management team shareholding and employee shareholding plan, which has a good incentive effect for the employees. Third, is the brand forest strategy that Yikang Enbei has been promoting, in the current market environment of consumption upgrading, including enteritis Ning, Jin Okang, Cherish Ming, Tian Baoning, Forefront Kang, Jindi and other brand products in a number of market segments continued to work hard, the results further appear.
, with the implementation of the Conebey brand's large variety project and the implementation of innovation-driven engineering based on research and development, the paradigm of Conebey's high growth is being called out. Kang Enbei said that the next step, the company will continue to adhere to the modern Chinese medicine and plant medicine-based business, while deeply expanding several initial advantages of the field of chemical treatment, and investment and business cooperation in the strategic way to intervene in the layout of the development of biopharmaceus business, give full play to the team, mechanism, products, brands, culture advantages, for The Enbe "moving group" of each car empowerment, and jointly achieve high-quality based on high-speed development. (New Kangjie)